Drug updated on 11/15/2023
|Tablet (oral; 150 mg nirmatrelvir co-packaged with 100 mg ritonavir)
| Ongoing and
- Indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
Product Monograph / Prescribing Information
|Paxlovid (nirmatrelvir, ritonavir) Prescribing Information.
|Pfizer Laboratories, Div Pfizer Inc., New York, NY
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
|Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)
|Annals of Clinical Microbiology and Antimicrobials
|Ritonavir-Boosted Nirmatrelvir (Paxlovid).
|Clinical Practice Guide for the Use of Therapeutics in Mild-Moderate COVID-19.
|BC Centre for Disease Control
|Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19.
|Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19.
|Ontario COVID-19 Science Advisory Table
|Drug Guideline – Use of nirmatrelvir and ritonavir tablets for COVID-19.
|NSW Therapeutic Advisory Group Inc and the Clinical Excellence Commission